详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Transcatheter rectal arterial chemoembolization with oxaliplatin and concurrent chemoradiotherapy in patients with locally advanced rectal cancer: A retrospective comparative study

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Cancer Center, Daping Hospital, Army Medical University, Chongqing, China [2]Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology, Chengdu, Sichuan, China [3]Department of Oncology, Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, China [4]Department of General Surgery, Colorectal Division, Daping Hospital, Army Medical University, Chongqing, China

出处：

DOI：

ISSN：

关键词： Locally advanced rectal cancer Chemoembolization Neoadjuvant chemoradiotherapy Pathological complete response Survival

摘要：

The aim of the study is to assess whether transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin could increase the pathologic complete response (pCR) rate of locally advanced rectal cancer (LARC) and improve survival outcomes, while minimizing adverse events compared to preoperative chemoradiotherapy (CRT) alone.Eligible LARC patients who received TRACE with oxaliplatin plus chemoradiotherapy (the NATRACE-CRT group) or preoperative CRT alone (the NA-CRT group) were retrospectively selected from the database of our institution. Pathological results, treatment-related adverse events and survival in the two groups were compared.A total of 236 patients were enrolled. The pCR rates were 18.38 % in the NATRACE-CRT group and 14.00 % in the NA-CRT group, with a non-significant difference of 4.38 % (P = 0.473). The median follow-up time was 42 months. The 5-year DFS (75.7 % vs. 73.2 %; P = 0.879) and OS (73.4 % vs. 70.3 %; P = 0.855) rates were comparable between the NATRACE-CRT group and the NA-CRT group. However, the NATRACE-CRT group had significantly fewer patients achieving TRG3 compared to the NA-CRT group (16.18 % vs. 35.00 %; P = 0.001). Furthermore, TRG3 patients in the NATRACE-CRT group exhibited significantly longer OS compared to those in the NA-CRT group (5-year OS: 88.9 % vs 59.5 %; P = 0.016).TRACE with oxaliplatin demonstrates potential in improving treatment response and prognosis of LARC patients with chemoradiotherapy resistance.Copyright © 2025. Published by Elsevier Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版：

无

最新[2023]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区外科

第一作者：

第一作者机构： [1]Cancer Center, Daping Hospital, Army Medical University, Chongqing, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Local tuning of radiomics-based model for predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer [2]Applicability of a pathological complete response magnetic resonance-based radiomics model for locally advanced rectal cancer in intercontinental cohort. [3]Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010) [4]Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy [5]Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy [6]MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study [7]Effect of Anemia on Tumor Response to Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer [8]Correlation between Lymph Node Regression Grading and Tumor Regression Grading after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer [9]局部进展期直肠癌术前"三明治"式neoCRTⅡ期临床研究中期疗效分析 [10]Construction and Evaluation of Nomogram for Hematological Indicators to Predict Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer